Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Osteoporosis 8Breast Neoplasms 5Bone Diseases, Metabolic 4Prostatic Neoplasms 3Prostatic Hyperplasia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteoporosis, Postmenopausal 1Lymphoma 1Lung Neoplasms 1Leukemia 1Esophageal Neoplasms 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

Dutasteride 4Prostatectomy 2proxalutamide 1polyphenon E 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Therapeutics 1Tamsulosin 1Standard of Care 1Risedronic Acid 1Psychiatric Rehabilitation 1Prostate-Specific Antigen 1Oxygen 1Nitrous Oxide 1Needles 1Microspheres 1Lycopene 1Levofloxacin 1Electroacupuncture 1Doxazosin 1Dexmedetomidine 1Celecoxib 1Biopsy 1Biofeedback, Psychology 1Amyloid 1Adrenergic alpha-Antagonists 1Acupuncture Therapy 15-alpha Reductase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Prostatic Hyperplasia × Risedronic Acid × Clear all
NCT00426777 2012-02-03

Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer

CMX Research

Phase 3 Completed
160 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡